Novonesis delivered 8% organic sales growth in the first nine months of 2025

Summary by AI BETAClose X

Novonesis delivered strong 8% organic sales growth for the first nine months of 2025, prompting an upward revision of its full-year organic sales growth outlook to 7-8%, from the previous 6-8%. This robust performance included a 37.3% adjusted EBITDA margin and a 22% increase in adjusted net profit, despite significant currency headwinds. The company also reported EUR 668.4 million in free cash flow before acquisitions and a NIBD/EBITDA of 2.0x. While indicating mid-single-digit organic sales growth for the fourth quarter due to favorable Q3 timing, the full-year adjusted EBITDA margin is now expected at the lower end of the 37-38% range, suggesting a positive operational trajectory.

Disclaimer*

UK 100

Latest directors dealings